Home
LSTA
LSTA News

Latest Lisata Therapeutics Inc. (LSTA) News on June 27, 2025

Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer

GlobeNewswire

a day ago

Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer

Lisata collaborates with GATC Health on drug development

Pharmaceutical Technology

9 days ago

Lisata collaborates with GATC Health on drug development

Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development

GlobeNewswire

10 days ago

Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development

Lisata Therapeutics to Present at the 2025 BIO International Convention

GlobeNewswire

16 days ago

Lisata Therapeutics to Present at the 2025 BIO International Convention

Lisata Therapeutics Inc (LSTA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Market ...

GuruFocus.com

2 months ago

Lisata Therapeutics Inc (LSTA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Market ...

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire

2 months ago

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025

GlobeNewswire

2 months ago

Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025

Will Lisata Therapeutics (NASDAQ:LSTA) Spend Its Cash Wisely?

Simply Wall St.

2 months ago

Will Lisata Therapeutics (NASDAQ:LSTA) Spend Its Cash Wisely?

Lisata Therapeutics Announces Research License with Catalent

GlobeNewswire

2 months ago

Lisata Therapeutics Announces Research License with Catalent

Lisata Therapeutics to Present at the Investival Showcase USA

GlobeNewswire

4 months ago

Lisata Therapeutics to Present at the Investival Showcase USA

Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development

GlobeNewswire

4 months ago

Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development

Lisata Therapeutics Inc (LSTA) Q4 2024 Earnings Call Highlights: Promising Developments Amid ...

GuruFocus.com

4 months ago

Lisata Therapeutics Inc (LSTA) Q4 2024 Earnings Call Highlights: Promising Developments Amid ...

Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire

4 months ago

Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025

GlobeNewswire

4 months ago

Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025

Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference

GlobeNewswire

5 months ago

Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference

Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma

GlobeNewswire

5 months ago

Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma

GlobeNewswire

5 months ago

Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics to Present at the 2025 Sequire Investor Summit

GlobeNewswire

5 months ago

Lisata Therapeutics to Present at the 2025 Sequire Investor Summit

US Penny Stocks To Watch In January 2025

Simply Wall St.

6 months ago

US Penny Stocks To Watch In January 2025

Lisata completes subject enrolment in multi-cancer trial of certepetide

Clinical Trials Arena

7 months ago

Lisata completes subject enrolment in multi-cancer trial of certepetide

Lisata Therapeutics Completes Enrollment for Cancer Therapy Trial

Exec Edge

7 months ago

Lisata Therapeutics Completes Enrollment for Cancer Therapy Trial

Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial

GlobeNewswire

7 months ago

Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial

Lisata and Kuva Labs partner for MR imaging agents to detect cancer

Medical Device Network

7 months ago

Lisata and Kuva Labs partner for MR imaging agents to detect cancer

MT Newswires

7 months ago

Lisata Therapeutics, Kuva Labs Collaborate on Cancer Diagnostics

Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging

GlobeNewswire

7 months ago

Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging

Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’

GlobeNewswire

7 months ago

Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’

Thomson Reuters StreetEvents

7 months ago

Q3 2024 Lisata Therapeutics Inc Earnings Call

Lisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost ...

GuruFocus.com

7 months ago

Lisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost ...

Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

7 months ago

Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration

GlobeNewswire

8 months ago

Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration

Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024

GlobeNewswire

8 months ago

Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024

Lisata Therapeutics, Inc. (LSTA) Upgraded to Buy: Here's What You Should Know

Zacks

8 months ago

Lisata Therapeutics, Inc. (LSTA) Upgraded to Buy: Here's What You Should Know

Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events

GlobeNewswire

8 months ago

Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events

Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis

GlobeNewswire

8 months ago

Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis

Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events

GlobeNewswire

9 months ago

Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events

Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial

GlobeNewswire

9 months ago

Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial

Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events

GlobeNewswire

10 months ago

Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events

Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma

GlobeNewswire

10 months ago

Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma

Will Lisata Therapeutics (NASDAQ:LSTA) Spend Its Cash Wisely?

Simply Wall St.

10 months ago

Will Lisata Therapeutics (NASDAQ:LSTA) Spend Its Cash Wisely?

Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

10 months ago

Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024

GlobeNewswire

a year ago

Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024

Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal

Zacks

a year ago

Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal

Lisata to use Haystack’s MRD tests for pancreatic cancer therapy trial

Medical Device Network

a year ago

Lisata to use Haystack’s MRD tests for pancreatic cancer therapy trial

Haystack Oncology, Lisata Therapeutics Collaborate on Pancreatic Cancer Therapy

Exec Edge

a year ago

Haystack Oncology, Lisata Therapeutics Collaborate on Pancreatic Cancer Therapy

Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy

GlobeNewswire

a year ago

Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy

EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy

Benzinga

a year ago

EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy

Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why

Zacks

a year ago

Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why

Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

GlobeNewswire

a year ago

Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model

GlobeNewswire

a year ago

Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model

Lisata Therapeutics Hits Enrollment Milestone for Pancreatic Cancer Trial

Exec Edge

a year ago

Lisata Therapeutics Hits Enrollment Milestone for Pancreatic Cancer Trial

Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial

GlobeNewswire

a year ago

Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial

Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events

GlobeNewswire

a year ago

Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events

MT Newswires

a year ago

Sector Update: Health Care Stocks Softer Late Afternoon

MT Newswires

a year ago

Lisata Therapeutics Receives European Medicines Agency Pediatric Waiver for Pancreatic Cancer Treatment

Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

GlobeNewswire

a year ago

Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2024 Earnings Call Transcript

Insider Monkey

a year ago

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2024 Earnings Call Transcript

Thomson Reuters StreetEvents

a year ago

Q1 2024 Lisata Therapeutics Inc Earnings Call

Lisata Therapeutics Net Loss Declines From a Year Earlier

Exec Edge

a year ago

Lisata Therapeutics Net Loss Declines From a Year Earlier

Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events

GlobeNewswire

a year ago

Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events

Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024

GlobeNewswire

a year ago

Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024

Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors

News Direct

a year ago

Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors

MT Newswires

a year ago

Lisata Therapeutics, Qilu Pharmaceutical Dose First Patient in China Trial of LSTA1 Plus Chemo for Pancreatic Cancer

Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

GlobeNewswire

a year ago

Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma

Zacks

a year ago

Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

GlobeNewswire

a year ago

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events

GlobeNewswire

a year ago

Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events

Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma

Zacks

a year ago

Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma

Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma

GlobeNewswire

a year ago

Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation

Simply Wall St.

a year ago

Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation

Life Science Virtual Investor Forum Presentations Now Available for Online Viewing

GlobeNewswire

a year ago

Life Science Virtual Investor Forum Presentations Now Available for Online Viewing

Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024

GlobeNewswire

a year ago

Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024

Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ

GlobeNewswire

a year ago

Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q4 2023 Earnings Call Transcript

Thomson Reuters StreetEvents

a year ago

Q4 2023 Lisata Therapeutics Inc Earnings Call

Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time

GlobeNewswire

a year ago

Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time

Lisata Therapeutics to Present at BIO CEO & Investor Conference

GlobeNewswire

a year ago

Lisata Therapeutics to Present at BIO CEO & Investor Conference

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 02/02/2024

180 Degree Capital Corp. Notes Average Discount of Net Asset Value Per Share to Stock Price for First Month of Initial Measurement Period of Its Discount Management Program

GlobeNewswire

a year ago

180 Degree Capital Corp. Notes Average Discount of Net Asset Value Per Share to Stock Price for First Month of Initial Measurement Period of Its Discount Management Program

Is Invitae Stock a Buy Now?

Motley Fool

a year ago

Is Invitae Stock a Buy Now?

HOME FEDERAL BANCORP, INC. OF LOUISIANA REPORTS RESULTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED DECEMBER 31, 2023

GlobeNewswire

a year ago

HOME FEDERAL BANCORP, INC. OF LOUISIANA REPORTS RESULTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED DECEMBER 31, 2023

11 Hyper-Growth Stocks Billionaires Are Loading Up On

Insider Monkey

a year ago

11 Hyper-Growth Stocks Billionaires Are Loading Up On

Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why

Zacks

a year ago

Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why

Texas Municipality Expands Use of Knightscope Emergency Communications

Business Wire

a year ago

Texas Municipality Expands Use of Knightscope Emergency Communications

GlobeNewswire

a year ago

Bannix Acquisition Corp. Announces Monthly Extension to Complete its Initial Business Combination

Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico

GlobeNewswire

a year ago

Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico

Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme

GlobeNewswire

a year ago

Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme

Flexsteel Industries, Inc. to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference; Releases Updated Investor Presentation

Business Wire

a year ago

Flexsteel Industries, Inc. to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference; Releases Updated Investor Presentation

Cheetah Mobile Further Invests in Beijing OrionStar

PR Newswire

a year ago

Cheetah Mobile Further Invests in Beijing OrionStar

Quince Therapeutics to Participate at Investor Events in January 2024

Business Wire

a year ago

Quince Therapeutics to Participate at Investor Events in January 2024

ACCESSWIRE

a year ago

Ideal Power Announces Plans for Upcoming Investor Conferences

Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy

GlobeNewswire

a year ago

Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy

PRINCIPAL REAL ESTATE INCOME FUND DECLARES MONTHLY DISTRIBUTIONS OF $0.105 PER SHARE

PR Newswire

a year ago

PRINCIPAL REAL ESTATE INCOME FUND DECLARES MONTHLY DISTRIBUTIONS OF $0.105 PER SHARE

Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides

GlobeNewswire

2 years ago

Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides

ACCESSWIRE

2 years ago

Stellantis Named Ideal Power Finalist in 2023 Stellantis Venture Awards

Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+

PR Newswire

2 years ago

Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+

Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma

GlobeNewswire

2 years ago

Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma

PR Newswire

2 years ago

Royce Micro-Cap Trust, Inc. (NYSE-RMT) declares Fourth Quarter Common Stock Distribution of $0.22 Per Share

Lisata Therapeutics to Present at NobleCon19 Investor Conference

GlobeNewswire

2 years ago

Lisata Therapeutics to Present at NobleCon19 Investor Conference

Share on Social Networks: